Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ERAS NASDAQ:MCRB NASDAQ:RZLT NASDAQ:TECX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeERASErasca$1.41-3.4%$1.38$1.01▼$3.45$413.60M1.051.60 million shs418,603 shsMCRBSeres Therapeutics$14.67-1.2%$8.75$6.53▼$30.60$129.68M2.75133,351 shs167,421 shsRZLTRezolute$5.11-3.9%$4.26$2.22▼$6.19$454.96M1.03662,289 shs717,567 shsTECXTectonic Therapeutic$21.44-7.3%$21.48$13.70▼$61.07$431.71M3.17189,739 shs325,293 shsBeginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceERASErasca-3.42%-3.42%-4.73%+20.51%-54.22%MCRBSeres Therapeutics-1.21%+26.47%+95.60%+83.42%-38.36%RZLTRezolute-3.95%+2.82%+21.67%+93.56%+5.36%TECXTectonic Therapeutic-7.27%+4.03%-2.06%+22.10%+28.77%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationERASErasca3.0933 of 5 stars3.52.00.00.02.82.51.3MCRBSeres Therapeutics3.4427 of 5 stars2.91.00.04.63.80.80.0RZLTRezolute2.5604 of 5 stars3.61.00.00.02.54.20.0TECXTectonic Therapeutic2.4906 of 5 stars3.71.00.00.03.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceERASErasca 3.00Buy$4.57224.21% UpsideMCRBSeres Therapeutics 1.75Reduce$73.67402.16% UpsideRZLTRezolute 3.14Buy$11.83131.57% UpsideTECXTectonic Therapeutic 3.33Buy$83.60289.93% UpsideCurrent Analyst Ratings BreakdownLatest MCRB, RZLT, ERAS, and TECX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025TECXTectonic TherapeuticRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$76.006/6/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$87.006/5/2025TECXTectonic TherapeuticLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/15/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$51.00 ➝ $85.005/14/2025ERASErascaGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$3.005/14/2025RZLTRezoluteWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$12.005/8/2025MCRBSeres TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Neutral$1.25 ➝ $6.004/30/2025ERASErascaHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$6.00 ➝ $6.004/28/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$14.00 ➝ $14.004/21/2025TECXTectonic TherapeuticMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$51.00(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookERASErascaN/AN/AN/AN/A$1.50 per shareN/AMCRBSeres Therapeutics$126.32M1.01N/AN/A$1.61 per share9.11RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ATECXTectonic TherapeuticN/AN/AN/AN/A$9.54 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateERASErasca-$161.65M-$0.62N/AN/AN/AN/A-36.56%-31.08%8/11/2025 (Estimated)MCRBSeres Therapeutics$140K-$4.60N/AN/AN/AN/A-41,084.76%-55.87%8/12/2025 (Estimated)RZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)TECXTectonic Therapeutic-$57.98M-$7.31N/AN/AN/AN/A-30.13%-27.52%8/13/2025 (Estimated)Latest MCRB, RZLT, ERAS, and TECX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/13/2025Q2 2025TECXTectonic Therapeutic-$0.98N/AN/AN/AN/AN/A8/12/2025Q2 2025MCRBSeres Therapeutics-$2.72N/AN/AN/AN/AN/A8/11/2025Q2 2025ERASErasca-$0.12N/AN/AN/AN/AN/A5/13/2025Q1 2025ERASErasca-$0.12-$0.11+$0.01-$0.11N/AN/A5/13/2025Q3 2025RZLTRezolute-$0.22-$0.27-$0.05-$0.27N/AN/A5/8/2025Q1 2025TECXTectonic Therapeutic-$1.10-$0.93+$0.17-$0.93N/AN/A5/7/2025Q1 2025MCRBSeres Therapeutics-$0.67-$2.24-$1.57$3.75$10.00 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthERASErascaN/AN/AN/AN/AN/AMCRBSeres TherapeuticsN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ATECXTectonic TherapeuticN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioERASErascaN/A12.3512.35MCRBSeres TherapeuticsN/A2.112.11RZLTRezoluteN/A8.438.43TECXTectonic TherapeuticN/A22.9222.92Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipERASErasca67.78%MCRBSeres Therapeutics59.34%RZLTRezolute82.97%TECXTectonic Therapeutic62.63%Insider OwnershipCompanyInsider OwnershipERASErasca14.40%MCRBSeres Therapeutics4.70%RZLTRezolute18.39%TECXTectonic Therapeutic9.20%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableERASErasca120283.29 million242.49 millionOptionableMCRBSeres Therapeutics3308.73 million8.32 millionOptionableRZLTRezolute4085.52 million69.79 millionOptionableTECXTectonic Therapeutic12018.67 million16.96 millionN/AMCRB, RZLT, ERAS, and TECX HeadlinesRecent News About These CompaniesTectonic Therapeutic (NASDAQ:TECX) Rating Increased to Hold at Wall Street ZenJuly 6, 2025 | americanbankingnews.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives $83.60 Average PT from AnalystsJuly 6, 2025 | americanbankingnews.comTectonic Therapeutic (NASDAQ:TECX) Upgraded to "Hold" at Wall Street ZenJuly 5, 2025 | marketbeat.comTectonic Therapeutic, Inc. (NASDAQ:TECX) Receives Average Recommendation of "Buy" from BrokeragesJuly 3, 2025 | marketbeat.comTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual Reconstitution - NasdaqJuly 1, 2025 | nasdaq.comTectonic Therapeutic joins Russell 3000 indexJune 30, 2025 | msn.comTectonic Therapeutic, Inc. Added to Russell 3000® Index Following Annual ReconstitutionJune 30, 2025 | quiverquant.comQTectonic Therapeutic Joins Russell 3000® IndexJune 30, 2025 | globenewswire.comRaymond James Resumes Coverage of Tectonic Therapeutic (TECX) With an Outperform RatingJune 25, 2025 | msn.comTectonic Therapeutic (NASDAQ:TECX) Stock Rating Lowered by Wall Street ZenJune 21, 2025 | marketbeat.comWe Think Tectonic Therapeutic (NASDAQ:TECX) Can Afford To Drive Business GrowthJune 15, 2025 | finance.yahoo.comTectonic Therapeutics (TECX) Gains Outperform Rating from Raymond James | TECX Stock NewsJune 10, 2025 | gurufocus.comLifeSci Capital Initiates Coverage of Tectonic Therapeutic (TECX) with Outperform RecommendationJune 7, 2025 | msn.comTectonic Therapeutic Holds 2025 Annual Stockholders MeetingJune 6, 2025 | tipranks.comTectonic Therapeutic (TECX) Receives Outperform Rating and $87 Price Target | TECX Stock NewsJune 5, 2025 | gurufocus.comTectonic Therapeutic Reports Q1 2025 Financial ResultsMay 30, 2025 | tipranks.comPromising Phase 1b Results and Market Potential Drive Buy Rating for Tectonic Therapeutic’s TX45May 22, 2025 | tipranks.comTectonic Therapeutic Announces Phase 1b Trial ResultsMay 19, 2025 | tipranks.comPromising Phase 1b Results and Favorable Safety Profile Justify Buy Rating for Tectonic TherapeuticMay 19, 2025 | tipranks.comAnalysts Offer Insights on Healthcare Companies: Tectonic Therapeutic (TECX) and Amgen (AMGN)May 17, 2025 | theglobeandmail.comTectonic Therapeutic Presents Complete Results for Positive Phase 1b Clinical Trial of TX45 in ...May 17, 2025 | gurufocus.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMCRB, RZLT, ERAS, and TECX Company DescriptionsErasca NASDAQ:ERAS$1.41 -0.05 (-3.42%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$1.37 -0.04 (-2.77%) As of 04:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead product is naporafenib which is in phase 1b trial for patients with RAS Q16X solid tumors and plans to initiate a pivotal Phase 3 trial for patients with NRASm melanoma. It also develops ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung and colorectal cancer, and advanced gastrointestinal malignancies; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. In addition, it is developing ERAS-801, a central nervous system-penetrant EGFR inhibitor which is in phase 1 clinical trials for the treatment of patients with recurrent glioblastoma multiforme. The company entered into license agreement with Novartis to develop, manufacture, use, and commercialize naporafenib; Katmai Pharmaceuticals, Inc. to develop, manufacture, use, and commercialize ERAS-801 and certain other related compounds; and NiKang Therapeutics, Inc. to develop and commercialize ERAS-601 and certain other related compounds. Erasca, Inc. was incorporated in 2018 and is headquartered in San Diego, California.Seres Therapeutics NASDAQ:MCRB$14.67 -0.18 (-1.21%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$15.12 +0.45 (+3.07%) As of 04:02 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.Rezolute NASDAQ:RZLT$5.11 -0.21 (-3.95%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$5.16 +0.05 (+0.98%) As of 07/15/2025 06:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.Tectonic Therapeutic NASDAQ:TECX$21.44 -1.68 (-7.27%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$20.80 -0.64 (-2.96%) As of 07/15/2025 05:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tectonic Therapeutic, Inc. engages in discovery and development of therapeutic proteins & antibodies. The company was founded by Timothy A. Springer and Andrew Kruse in 2019 and is headquartered in Watertown, MA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Pelosi Makes Big Bet on Broadcom—Here’s Why It Matters 3 Analysts Set $600 Target Ahead of Microsoft Earnings JPMorgan Q2 Results Affirm Dividend, Buybacks, & Growth NVDA Greenlight: China H20 Sales Spark 50% Rally Potential Tesla: 2 Plays Ahead of Next Week's Earnings Report New Catalyst Sends Joby Stock to 52-Week Highs Palantir Gets Price Hike From Wedbush Amid High Valuation Fastenal Surges After Earnings Beat, Tariff Risks Loom Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
